New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
17:04 EDTSUPN, UTHRSupernus receives $2M milestone payment for launch of Orenitram
Supernus Pharmaceuticals (SUPN) announced that United Therapeutics Corporation (UTHR) has paid Supernus a $2M milestone payment under United Therapeutics' license agreement with Supernus. This payment was due upon the launch of Orenitram Extended-Release Tablets for the treatment of pulmonary arterial hypertension, in the United States. Orenitram utilizes a Supernus patented technology platform. In addition to the launch milestone, Supernus will receive royalties on net sales of Orenitram, and may become entitled to additional milestone payments.
News For SUPN;UTHR From The Last 14 Days
Check below for free stories on SUPN;UTHR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
07:38 EDTSUPNSupernus announces paragraph IV Abbreviated NDA filing for Trokendi XR
Subscribe for More Information
August 18, 2014
11:41 EDTUTHRCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 14, 2014
09:11 EDTSUPNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
07:37 EDTSUPNSupernus receives FDA fast track designation for SPN-810
Supernus Pharmaceuticals announced that the United States Food and Drug Administration has granted fast track designation for SPN-810 for the treatment of impulsive aggression in attention deficit hyperactivity disorder. This product candidate is expected to enter Phase III testing, with patient dosing commencing during 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use